Download PDF
Thromb Haemost 1998; 80(06): 881-886
DOI: 10.1055/s-0037-1615382
Letters to the Editor
Schattauer GmbH

Augmented Platelet Aggregation as Predictor of Reocclusion after Thrombolysis in Acute Myocardial Infarction

Thomas K. Nordt
1   From the Abteilung Kardiologie, Medizinische Klinik und Poliklinik, Ruprecht-Karls-Universität Heidelberg, Germany
,
Martin Moser
1   From the Abteilung Kardiologie, Medizinische Klinik und Poliklinik, Ruprecht-Karls-Universität Heidelberg, Germany
,
Benedikt Kohler
1   From the Abteilung Kardiologie, Medizinische Klinik und Poliklinik, Ruprecht-Karls-Universität Heidelberg, Germany
,
Johannes Ruef
1   From the Abteilung Kardiologie, Medizinische Klinik und Poliklinik, Ruprecht-Karls-Universität Heidelberg, Germany
,
Karlheinz Peter
1   From the Abteilung Kardiologie, Medizinische Klinik und Poliklinik, Ruprecht-Karls-Universität Heidelberg, Germany
,
Wolfgang Kübler
1   From the Abteilung Kardiologie, Medizinische Klinik und Poliklinik, Ruprecht-Karls-Universität Heidelberg, Germany
,
Christoph Bode
1   From the Abteilung Kardiologie, Medizinische Klinik und Poliklinik, Ruprecht-Karls-Universität Heidelberg, Germany
› Author Affiliations
Further Information

Publication History

Received 05 February 1998

Accepted after resubmission 21 August 1998

Publication Date:
07 December 2017 (online)

    Permissions and Reprints

Summary

Rationale. Reocclusion after thrombolysis diminishes the benefits of early reperfusion after acute myocardial infarction (AMI). No clinical or laboratory variables have been identified as predictors for reocclusion yet. Methods and results. To evaluate hemostatic variables as potential risk determinants platelet aggregation (PA, representing platelet activity), thrombin/antithrombin complexes (TAT, representing thrombin generation), and plasminogen activator inhibitor type 1 (PAI-1, representing endogenous fibrinolysis) were determined in 31 patients with AMI at 0, 1, 2, and 12 h after the start of thrombolysis as well as at hospital discharge. Reocclusion (defined as reinfarction or angiographically confirmed, clinically silent coronary reocclusion) occurred in 5 patients within 5-14 days and in 8 patients within 1 year. TAT plasma concentrations were lower in patients with reocclusion than in those without (9.9 ± 5.7 vs. 22.9 ± 22.2 ng/ml at 2 h, 6.5 ± 3.1 vs. 11.2 ± 6.4 ng/ml at 12 h, means ± SD, p <0.05 each). Neither concentration nor activity of PAI-1 in plasma differed between both patient groups. However, both slope and maximum of PA (induced by 2 μmol/l ADP) were augmented in patients with reocclusion (slope: 39.4 ± 1.7 vs. 32.5 ± 7.4 at 2 h, p <0.001; 42.6 ± 2.6 vs. 36.6 ± 8.9 at 12 h, p <0.01). Results were independent of the thrombolytic agent used (alteplase or reteplase). A PA slope at 2 h higher than the average slope before thrombolysis (37.2 ± 5.7) could be identified as best predictor for early (within 5-14 d, p = 0.017, sensitivity 1.00, specificity 0.69) and late reocclusion (within 1 y, p=0.009, 0.88 and 0.74, respectively). Conclusions. Increased PA following coronary thrombolysis appears to be associated with early and late reocclusion. This marker could be useful in identifying patients who may benefit from more aggressive anti-platelet (such as GP IIb/IIIa receptor antagonists), interventional, or both strategies.

 

  • References

  • 1 Gruppo Italiano Per Lo Studio Della Streptochi-Nasi Nell’Infarto Miocardico (GISSI).. Long-term effects of intravenous thrombolysis in acute myocardial infarction: Final report of the GISSI study.. Lancet 1987; ii: 871-4.
    PubMedGoogle Scholar
  • 2 ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17187 cases of suspected acute myocardial infarction: ISIS-2.. Lancet 1988; ii: 349-60.
    PubMedGoogle Scholar
  • 3 Barbash GI, Hod H, Roth A, Miller HI, Rath S, Har Zahav Y, Modan M, Zivelin A, Laniado S, Seligsohn U. Correlation of baseline plasminogen activator inhibitor activity with patency of the infarct artery after thrombolytic therapy in acute myocardial infarction.. Am J Cardiol 1989; 64: 1231-5.
    CrossrefPubMedGoogle Scholar
  • 4 Sane DC, Stump DC, Topol EJ, Sigmon KN, Kereiakes DJ, George BS, Mantell SJ, Macy E, Collen D, Califf RM. Correlation between baseline plasminogen activator inhibitor levels and clinical outcome during therapy with tissue plasminogen activator for acute myocardial infarction.. Thromb Haemost 1991; 65: 275-9.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Bode C, Smalling RW, Berg G, Burnett C, Lorch G, Kalbfleisch JM, Chernoff R, Christie LG, Feldman RL, Seals AA. Weaver WD for the RAPID II Investigators.. Randomized comparison of coronary thrombolysis achieved with double bolus reteplase (r-PA) and front-loaded, accelerated alteplase (rt-PA) in patients with acute myocardial infarction.. Circulation 1996; 94: 891-8.
    CrossrefPubMedGoogle Scholar
  • 6 The TIMI Study Group.. The thrombolysis in myocardial infarction (TIMI) trial. Phase I findings.. N Engl J Med 1985; 312: 932-6.
    PubMedGoogle Scholar
  • 7 Nordt TK, Schneider DJ, Sobel BE. Augmentation of the synthesis of plasminogen activator inhibitor type-1 by precursors of insulin. A potential risk factor for vascular disease.. Circulation 1994; 89: 321-30.
    CrossrefPubMedGoogle Scholar
  • 8 Rapold HJ, Grimaudo V, Declerck PJ, Kruithof EKO, Bachmann F. Plasma levels of plasminogen activator inhibitor type 1, β-thromboglobulin, and fibrinopeptide A before,during, and after treatment of acute myocardial infarction with alteplase.. Blood 1991; 78: 1490-5.
    PubMedGoogle Scholar
  • 9 Huber K, Beckmann R, Rauscha F, Probst P, Kaindl F, Binder BR. The role of type-1 plasminogen activator inhibitor in failure of thrombolytic therapy with recombinant tissue plasminogen activator.. Z Kardiol 1993; 82 (Suppl. 02) 195-200.
    PubMedGoogle Scholar
  • 10 Hirashima O, Ogawa H, Oshima S, Sakamoto T, Honda Y, Sakata S, Masuda T, Miyao Y, Yasue H. Serial changes of plasma plasminogen activator inhibitor activity in acute myocardial infarction: Difference between thrombolytic therapy and direct coronary angioplasty.. Am Heart J 1995; 130: 933-9.
    CrossrefPubMedGoogle Scholar
  • 11 Verheugt FWA, Meijer A, Lagrand WK, van Eenige MJ. Reocclusion: The flip side of coronary thrombolysis.. J Am Coll Cardiol 1996; 27: 766-73.
    CrossrefPubMedGoogle Scholar
  • 12 Rivers JT, White HD, Cross DB, Williams BF, Norris RM. Reinfarction after thrombolytic therapy for acute myocardial infarction followed by conservative management: Incidence and effect of smoking.. J Am Coll Cardiol 1990; 16: 340-8.
    CrossrefPubMedGoogle Scholar
  • 13 Eisenberg PR. Mechanisms of reocclusion after coronary thrombolysis.. Z Kardiol 1993; 82 (Suppl. 02) 175-8.
    PubMedGoogle Scholar
  • 14 Kerins DM, Roy L, FitzGerald GA, Fitzgerald DJ. Platelet and vascular function during coronary thrombolysis with tissue-type plasminogen activator.. Circulation 1989; 80: 1718-25.
    CrossrefPubMedGoogle Scholar
  • 15 Fitzgerald DJ, Catella F, Roy L, FitzGerald GA. Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction.. Circulation 1988; 77: 142-50.
    CrossrefPubMedGoogle Scholar
  • 16 Fujii S, Sawa H, Saffitz JE, Lucore CL, Sobel BE. Induction of endothelial cell expression of the plasminogen activator inhibitor type 1 gene by thrombosis in vivo.. Circulation 1992; 86: 2000-10.
    CrossrefPubMedGoogle Scholar
  • 17 Brouwer MA, Böhncke JR, Veen G, Meijer A, van Eenige MJ, Verheugt FWA. Adverse long-term effects of reocclusion after coronary thrombolysis.. J Am Coll Cardiol 1995; 26: 1440-4.
    CrossrefPubMedGoogle Scholar
  • 18 Terres W, Lund GK, Hübner A, Ehlert A, Reuter H, Hamm CW. Endogenous tissue plasminogen activator and platelet reactivity as risk factors for reocclusion after recanalization of chronic total coronary occlusions.. Am Heart J 1995; 130: 711-6.
    CrossrefPubMedGoogle Scholar
  • 19 White HD, French JK, Hamer AW, Brown MA, Williams BF, Ormiston JA, Cross DB. Frequent reocclusion of patent infarct-related arteries between 4 weeks and 1 year: Effects of antiplatelet therapy.. J Am Coll Cardiol 1995; 25: 218-23.
    CrossrefPubMedGoogle Scholar
  • 20 Eisenberg PR, Sobel BE, Jaffe AS. Activation of prothrombin accompanying thrombolysis with recombinant tissue-type plasminogen activator.. J Am Coll Cardiol 1992; 19: 1065-9.
    CrossrefPubMedGoogle Scholar
  • 21 Gulba DC, Barthels M, Westhoff-Bleck M, Jost S, Rafflenbeul W, Daniel WG, Hecker H, Lichtlen PR. Increased thrombin levels during thrombolytic therapy in acute myocardial infarction. Relevance for the success of therapy.. Circulation 1991; 83: 937-44.
    CrossrefPubMedGoogle Scholar
  • 22 Merlini PA, Bauer KA, Oltrona L, Ardissino D, Spinola A, Cattaneo M, Broccolino M, Mannucci PM, Rosenberg RD. Thrombin generation and activity during thrombolysis and concomitant heparin therapy in patients with acute myocardial infarction.. J Am Coll Cardiol 1995; 25: 203-9.
    CrossrefPubMedGoogle Scholar
  • 23 Gray RP, Yudkin JS, Patterson DL. Enzymatic evidence of impaired reper-fusion in diabetic patients after thrombolytic therapy for acute myocardial infarction: A role for plasminogen activator inhibitor?. Br Heart J 1993; 70: 530-6.
    CrossrefPubMedGoogle Scholar